» Articles » PMID: 25705847

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation

Abstract

The microphthalmia-associated transcription factor (MITF) is a key regulator of melanocyte development and a lineage-specific oncogene in melanoma; a highly lethal cancer known for its unpredictable clinical course. MITF is regulated by multiple intracellular signaling pathways, although the exact mechanisms that determine MITF expression and activity remain incompletely understood. In this study, we obtained genome-wide DNA methylation profiles from 50 stage IV melanomas, normal melanocytes, keratinocytes, and dermal fibroblasts and utilized The Cancer Genome Atlas data for experimental validation. By integrating DNA methylation and gene expression data, we found that hypermethylation of MITF and its co-regulated differentiation pathway genes corresponded to decreased gene expression levels. In cell lines with a hypermethylated MITF-pathway, overexpression of MITF did not alter the expression level or methylation status of the MITF pathway genes. In contrast, however, demethylation treatment of these cell lines induced MITF-pathway activity, confirming that gene regulation was controlled via methylation. The discovery that the activity of the master regulator of pigmentation, MITF, and its downstream targets may be regulated by hypermethylation has significant implications for understanding the development and evolvement of melanoma.

Citing Articles

DNA methylation variations of DNA damage response correlate survival and local immune status in melanomas.

Wang M, Zhang X, Yang H, Li Y, Chen W, Yin A Immun Inflamm Dis. 2024; 12(9):e1331.

PMID: 39254643 PMC: 11386344. DOI: 10.1002/iid3.1331.


Identification of a CpG-based signature coupled with gene expression as prognostic indicators for melanoma: a preliminary study.

Lin Z, Yang L Sci Rep. 2024; 14(1):5302.

PMID: 38438381 PMC: 10912562. DOI: 10.1038/s41598-023-50614-2.


Restrained Mitf-associated autophagy by Mulberroside A ameliorates osteoclastogenesis and counteracts OVX-Induced osteoporosis in mice.

Xue H, Feng Z, Yuan P, Qiao L, Lou Q, Zhao X Cell Death Discov. 2024; 10(1):80.

PMID: 38360705 PMC: 10869803. DOI: 10.1038/s41420-024-01847-1.


Current understanding of epigenetics role in melanoma treatment and resistance.

Karami Fath M, Azargoonjahromi A, Soofi A, Almasi F, Hosseinzadeh S, Khalili S Cancer Cell Int. 2022; 22(1):313.

PMID: 36224606 PMC: 9555085. DOI: 10.1186/s12935-022-02738-0.


DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype.

Sanna A, Phung B, Mitra S, Lauss M, Choi J, Zhang T JCI Insight. 2022; 7(19).

PMID: 36040798 PMC: 9675437. DOI: 10.1172/jci.insight.156577.


References
1.
Noushmehr H, Weisenberger D, Diefes K, Phillips H, Pujara K, Berman B . Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17(5):510-22. PMC: 2872684. DOI: 10.1016/j.ccr.2010.03.017. View

2.
Sharma S, Lee D, Li B, Quinlan M, Takahashi F, Maheswaran S . A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141(1):69-80. PMC: 2851638. DOI: 10.1016/j.cell.2010.02.027. View

3.
Conway K, Edmiston S, Khondker Z, Groben P, Zhou X, Chu H . DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res. 2011; 24(2):352-60. PMC: 3073305. DOI: 10.1111/j.1755-148X.2011.00828.x. View

4.
Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16. PMC: 3549296. DOI: 10.1056/NEJMoa1103782. View

5.
Bonazzi V, Nancarrow D, Stark M, Moser R, Boyle G, Aoude L . Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. PLoS One. 2011; 6(10):e26121. PMC: 3197591. DOI: 10.1371/journal.pone.0026121. View